Actively Recruiting
Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors Using PET Imaging Targeting LRRC15 in Malignant Tumors
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2026-04-27
26
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the clinical application of PET imaging targeting LRRC15 in patients with various malignant tumors, including pancreatic, breast, lung, sarcoma, head and neck tumors, glioblastoma, colorectal cancer, and melanoma. The study also includes healthy volunteers to assess the biodistribution and safety of LRRC15-specific radiotracers. The goal is to improve diagnosis, staging, and therapeutic decision-making by comparing these imaging results with established methods and histopathology. The study uses LRRC15-specific PET radiotracers for PET/MR or PET/CT imaging. Patients with suspected or confirmed malignancies undergo imaging to detect lesions, determine disease stage, and assess tumor burden. Healthy volunteers participate for pharmacokinetic analyses to understand how the radiotracer distributes and metabolizes in the body and to evaluate its safety. The study includes patients and volunteers aged 18 and older. Participants will undergo imaging procedures as part of the study, with evaluations including visual and standardized uptake values of lesions and biodistribution over a one-year period. The study monitors the imaging results against histopathological diagnosis and compares with other PET methods such as [18F]FDG PET or [68Ga]Ga-FAPI PET. Safety and metabolic patterns of the radiotracer are also assessed. The total study duration extends to March 2027, with ongoing cooperation required from participants throughout.
CONDITIONS
Brief Title
Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Capable of providing signed informed consent or have a legally authorized representative
- Willing and able to comply with all study procedures throughout the study
- Adult patients or healthy volunteers aged 18 years or older, any gender
- Patients with clinically suspected or confirmed malignancies supported by tumor markers, imaging, or pathology, and in good general condition
- Women of childbearing potential must use effective contraception for at least one month before screening and continue during and after the study
- Must meet any other protocol-specified inclusion criteria
You will not qualify if you...
- Unable to tolerate or complete PET/MR or PET/CT exams (e.g., inability to lie supine, claustrophobia, radiophobia)
- Presence of acute systemic illnesses or electrolyte imbalances
- Known allergy or hypersensitivity to LRRC15 radiotracer or its components
- Fasting blood glucose exceeding 11.0 mmol/L before [18F]FDG injection
- Poor expected compliance as judged by the investigator
- Pregnant or breastfeeding women
- Any other conditions making participation unsuitable as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo PET/MR or PET/CT imaging using LRRC15-specific targeted PET radiotracers to evaluate lesions and biodistribution.
1 imaging visit (in-person)
Duration - 1 year
Participants are monitored for one year after imaging to assess outcomes related to lesion uptake and biodistribution.
Follow-up visits as needed
Trial Site Locations
Total: 1 location
1
Wuhan Union Hospital, China
Wuhan, Hubei, China, 430030
Actively Recruiting
Research Team
X
Xiaoli Lan, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here